June 30, 2010 -- About half of older people with memory loss who meet the clinical definition of mild cognitive impairment will develop Alzheimer’s disease within five years, but predicting who will and will not progress to dementia remains a challenge.
Genetic, biochemical, and brain imaging analyses all have some value in measuring cognitive decline, but the predictive value of these tests for identifying patients who will progress to Alzheimer’s disease has not been clear until now.
In one of the largest studies ever to compare the tests, researchers from the University of California-Berkeley found that word-recollection memory testing combined with PET scans of the brain was best able to predict who would develop Alzheimer’s disease.
Study participants whose PET scans and memory tests were abnormal were nearly 12 times more likely to develop Alzheimer’s disease than people whose scores on both tests were normal.
“These two tests were highly predictive of progression to Alzheimer’s disease in people with mild cognitive impairment,” researcher Susan M. Landau, PhD, of the University of California-Berkeley, tells WebMD.
Landau and colleagues analyzed data from a large trial known as the Alzheimer’s Disease Neuroimaging Initiative, designed to evaluate the various brain imaging tests now being evaluated for diagnosing Alzheimer’s disease.
The study included 85 mostly elderly people with mild cognitive impairment, a medical term used to describe a state of memory loss or other cognitive decline that is greater than would be expected with normal aging but has not yet progressed to dementia.
All the study participants had five different tests:
An "episodic memory test," which involved recalling a list of words
A blood test to identify a variant of the ApoE gene that has been linked to Alzheimer’s disease
An MRIbrain scan to measure the size of the area of the brain associated with memory and learning, known as the hippocampus
A PET scan of the brain to detect metabolic changes thought to be associated with Alzheimer’s
A spinal tap performed to measure proteins found in spinal fluid that are believed to play a key role in Alzheimer’s disease
"These tests have all shown promise for predicting Alzheimer’s disease, but they have never been compared to each other before,” Landau says.